文献速递关节外科

初次单侧全髋与全膝关节置换围手术期使用四氢大麻酚和大麻二酚产品的情况

Use of Tetrahydrocannabinol and Cannabidiol Products in the Perioperative Period Around Primary Unilateral Total Hip and Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2020-02-05

这项前瞻性队列研究纳入195例初次单侧全髋或全膝关节置换患者,回顾性调查围手术期CBD/THC产品使用情况。结果显示22.6%的TKA和11.7%的THA患者使用过此类产品,使用模式多样,但使用与未使用者在阿片类药物用量、疼痛评分、追加处方比例及住院时长上均无显著差异。

要点

  • 围手术期CBD/THC使用率:TKA 22.6%,THA 11.7%,总体16.4%。
  • CBD/THC使用者与未使用者阿片需求及疼痛评分无显著差异。
  • 使用模式多样,样本量小,需进一步研究其影响。

核心结论

  • 在本小样本中,围手术期使用CBD/THC产品与阿片类药物需求无显著关联。

研究设计与样本

  • 单中心前瞻性队列纳入初次单侧THA/TKA患者,对完成详细疼痛日记者回顾性调查CBD/THC使用情况。

主要发现

  • 210例中195例(92.9%应答率)数据被分析,总体16.4%使用CBD/THC产品。
  • TKA患者使用率为22.6%(n=19),THA患者为11.7%(n=13)。
  • 使用者中用药模式多样;使用者与非使用者在麻醉药品使用时长、总MME、药片数、平均术后疼痛评分、需追加麻醉处方比例及住院时长上均无显著差异。

临床怎么用

  • 临床应主动询问关节置换患者围手术期CBD/THC使用情况,但无需据此预判阿片需求变化。

局限性

  • 样本量小(195例),可能不足以检测出微小效应。
  • 为回顾性调查CBD/THC使用,存在回忆偏倚。
  • 单中心研究,使用模式异质性大,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the opioid crisis in America, patients are trying alternative medications including tetrahydrocannabinol (THC) and other cannabidiol (CBD) containing products in the perioperative period, especially in states where these products are legal. This study sought to analyze usage rates of CBD/THC products in the perioperative period for primary unilateral total hip and knee arthroplasty (THA/TKA) patients and identify a possible association with post-operative opioid use. METHODS: A prospective cohort of primary unilateral THA/TKA patients were enrolled at a single institution. Patients who completed detailed pain journals were retrospectively surveyed for CBD/THC product usage. Pain medications were converted to morphine milligram equivalents (MME). RESULTS: Data from 195 of the 210 patients (92.9% response rate) following primary arthroplasty were analyzed. Overall, 16.4% of arthroplasty-22.6% (n = 19) of TKA and 11.7% (n = 13) of THA-patients used CBD/THC products in the perioperative period. There was a wide variety of usage patterns among those using CBD/THC products. In comparing CBD/THC users and non-users, there was no significant difference in the length of narcotic use, total morphine milligram equivalents taken, narcotic pills taken, average post-op pain scores, the percentage of patients requiring a refill of narcotics, or length of stay. CONCLUSION: Understanding that CBD/THC usage was not consistent for patients who used these products, 22.6% of TKA and 11.7% of THA patients tried CBD/THC products in the perioperative period. In this small sample, CBD/THC use was not associated with a major effect on narcotic requirements. Further studies on the effects of CBD/THC are needed as these therapies become more widely available.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Runner RP, Luu AN, Nassif NA, et al. Use of Tetrahydrocannabinol and Cannabidiol Products in the Perioperative Period Around Primary Unilateral Total Hip and Knee Arthroplasty. J Arthroplasty. 2020. PMID: 32173619. doi:10.1016/j.arth.2020.01.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。